Last reviewed · How we verify
NCT03883048
Idiopathic Bronchiectasis and Pulmonary Hypertension
trial testing Observation of bronchiectasis with pulmonary hypertension in Bronchiectasis in 1,606 participants. Completed in 31 December 2021.
31 December 2021
Quick facts
| Lead sponsor | Shanghai Pulmonary Hospital, Shanghai, China |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,606 |
| Start date | 1 June 2018 |
| Primary completion | 31 December 2021 |
| Estimated completion | 31 December 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Observation of bronchiectasis with pulmonary hypertension
Conditions studied
- Bronchiectasis — all drugs for Bronchiectasis →
- Pulmonary Hypertension — all drugs for Pulmonary Hypertension →
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Who can join
18 and older, any sex, with Bronchiectasis or Pulmonary Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with idiopathic bronchiectasis who received right heart catheterization (RHC) were included to evaluate the consistency between pulmonary arterial pressure (PAP) and other noninvasive indicators (pulmonary arterial systolic pressure \[PASP\] calculated by echocardiography, main pulmonary artery \[MPA\] diameter and MPA/ascending aorta ratio on chest high-resolution computed tomography \[HRCT\]). Then the optimal noninvasive indicator for identify PH was determined and its critical point was obtained according to the Youden Index. Based on this, we investigate the proportion, risk factors and prognosis of PH in idiopathic bronchiectasis patients in another large-scale population.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The Utility of Echocardiography in Patients with Pulmonary Hypertension Secondary to Idiopathic bronchiectasis
Bai J, Mao B, Gao Y, Wang L, et al · · 2024 · DOI 10.21203/rs.3.rs-3862210/v1
Verify or expand the search:
- PubMed search for NCT03883048
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Bronchiectasis
Currently open trials in the same condition.
- NCT07283497 — Itraconazole Therapy In Bronchiectasis With Airway Mold · Phase 4 · recruiting
- NCT07188675 — Functional Inspiratory Training in Bronchiectasis · NA · recruiting
- NCT06897761 — Development of an Interactive Digital Respiratory Game and Device and Investigation of Its Effectiveness in Children Wit · NA · recruiting
- NCT07147803 — Sleep Quality in Patients With Non-cystic Fibrosis Bronchiectasis · active not recruiting
- NCT07274631 — A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine · recruiting
Other Shanghai Pulmonary Hospital, Shanghai, China trials
Trials by the same sponsor.
- NCT07469488 — A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-M · Phase 4 · not yet recruiting
- NCT07494591 — TEAS for Ipsilateral Shoulder Pain After Video-Assisted Thoracoscopic Lung Surgery · NA · not yet recruiting
- NCT07517640 — Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial · Phase 2 · not yet recruiting
- NCT07393438 — Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) · Phase 2 · not yet recruiting
- NCT07375979 — A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-cente · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03883048 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Pulmonary Hospital, Shanghai, China
- Last refreshed: 3 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03883048.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing